Revenue was nearly quadruple the level in the same quarter last year
Featured articles
US regulators have given the green light for the opioid Dsuvia to be used under strict medical...
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the...
The treatment Zynberba is developing is for Fragile X Syndrome, the leading known genetic cause...
Its Phase 3 clinical trial of eye disease drug Xipere failed to meet its primary endpoint
New data will be unveiled later Monday at a cancer conference in Glasgow
Featured companies
Sphere Medical is a dynamic company specialising in the development of innovative medical moni...
![rgs[LOGO]200x100.jpg](/thumbs/upload/Company/Logo/2016_10//200x200_rgs%5BLOGO%5D200x100.jpg){kind=logo}
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfoli...
Sativa seeks to invest in companies which are well-placed to take advantage of the dynamic reg...
Collagen Solutions develops, manufactures and supplies medical grade collagen biomaterials for...
Clinigen Group plc is a rapidly-growing global pharmaceutical and services company with a uniq...
Ventripoint (TSXV: VPT) has redesigned VMS to meet the demands of every market. Preparin...
Global biotech Newswire
Revenue was nearly quadruple the level in the same quarter last year
AcelRx shares pop on FDA approval of opioid pain treatment Dsuvia
November 05 2018
US regulators have given the green light for the opioid Dsuvia to be used under strict medical...
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the...
The treatment Zynberba is developing is for Fragile X Syndrome, the leading known genetic cause...
Dr Lang is an internationally renowned cardiologist and specialist in echocardiography..
Aequus Pharmaceuticals establishes advisory board in ophthalmology
November 05 2018
They are Dr Ike Ahmed who will become chairman and Dr Rosa Braga-Mele, who comes from the...
Its Phase 3 clinical trial of eye disease drug Xipere failed to meet its primary endpoint
N4 Pharma surges as MedImmune agrees to extend collaboration deal
November 05 2018
The two parties had been working together as part of a project funded by the UK government and...
Having complete ownership of the US subsidiary is particularly important, said Angle, as it owns...
Executive video interviews
In part two of two announcements concerning Orgenesis (NASDAQ: ORGS) and HemoGenyx...
In part one of two announcements concerning Orgenesis (NASDAQ: ORGS) and HemoGenyx...
Collagen Solutions PLC (LON:COS) CEO Jamal Rushdy and CFO Hilary Spence speak to...
Manx Telecom (LON:MANX) chief executive Gary Lamb speaks to Proactive Investors about...
Dr Markku Jalkanen, CEO of Faron Pharmaceuticals Oy (LON:FARN), tells Proactive London's...
Biotech Actinogen has signed 174 patients for its trial of the drug Xanamem, which may...
Medlab Clinical (ASX:MDC) has completed the first stage medical trials of its NanaBis...
Small cap names on the move today are: Pyxus (NYSE:PYX), Acorda Therapeutics...
Arix Bioscience Plc (LON:ARIX) portoflio company Iterum Therapeutics Plc (NASDAQ:ITRM)...
Orgenesis Inc (NASDAQ:ORGS) CEO Vered Caplan and General Manager Ohad Karnieli tells...
Futura Medical PLC's (LON:FUM) finance director and chief operating officer Angela...
Iterum Therapeutics Plc (NASDAQ:ITRM) CEO Corey Fishman tells Proactive's Christine...
Big picture investment ideas in Biotech Capital
The readout of clinical trials is expected this month.
Since September, the group's portfolio has steamed ahead with a number of new and successful...
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash...
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty...
The Australian regenerative medicine company is developing a portfolio of innovative cellular...
The company made positive operational progress in the year to June 30.
“It’s a blended model of highly cash generative assets and top line growth”
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that...
The goal of the program is to extend the visualization extracted from 2D ultrasound images and...
Capital Network Research
Avacta Group - Maximising Affimer's potential across therapeutics and...
October 03 2018
Over the last year or so, management has delivered significant progress in bringing their...
Judges Scientific PLC - 2018 Interim Results
September 21 2018
Judges Scientific reported results for the first half of 2018. The period included a...
Legendary Investments - Hidden value potential
September 03 2018
Legendary Investments (LON:LEG) creates value through privately held and pre-market...
Avacta Group - Exciting partnership with Bach BioSciences
July 30 2018
Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with...
Avacta Group - Rapid Progress of Immuno-oncology Programs
April 16 2018
KEY INVESTOR MESSAGES
Faster than expected development of the second immuno-oncology...
Summit Therapeutics Plc - Stock Valuation Undemanding
April 03 2018
- Key inflection point: topline data readout from the PhaseOut DMD phase 2 trial in Duchenne...
Partners:
